The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:956-959 March 1, 2007 Number 9
NextNext

Chronic Kidney Disease, Anemia, and Epoetin

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Drüeke, T. B.
-Related Article
by Singh, A. K.
-PubMed Citation
To the Editor: In their report on the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial, which evaluated the use of recombinant erythropoietin (epoetin alfa) to treat anemia in patients with chronic kidney disease, Singh et al. (Nov. 16 issue)1 make no mention of heme iron polypeptide, an oral iron preparation. It is thought that free-radical–induced oxidative stress from intravenous iron may be responsible for tissue damage in patients with chronic kidney disease. Data in Table 1 of the article suggest that patients with a target hemoglobin level of 11.3 g per deciliter (the low-hemoglobin group) received less . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.